Abstract
Dihydroergotamine (DHE) prescribing information contains a boxed warning regarding the possibility of serious and/or life‐threatening peripheral ischemia with co‐administration of strong cytochrome P450 3A4 (CYP3A4) inhibitors. The effects of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics and safety of nasally administered STS101 (DHE) were evaluated in this open‐label, 2‐period, fixed sequence study in 31 healthy participants. Following a single dose of 5.2 mg STS101, DHE exposure when co‐administered with itraconazole was 119% and 114% of that when administered alone, for the area under the plasma concentration–time curve from time 0 to infinity (AUC0–inf), and maximum observed plasma concentration (Cmax), respectively. Co‐administration of STS101 with itraconazole was not associated with an increase in the frequency of treatment emergent adverse events compared with STS101 alone. No clinically significant findings of a single dose of 5.2 mg STS101 alone or with itraconazole were observed on nasal examinations, safety laboratory values, vital signs, or safety electrocardiograms. In this study, no clinically meaningful drug–drug interactions were seen when STS101 was co‐administered with a strong CYP3A4 inhibiting drug.
Keywords: CYP3A4, DHE, dihydroergotamine mesylate, drug interactions, intranasal, itraconazole, migraine, pharmacokinetics
Introduction
Dihydroergotamine (DHE) mesylate is a second‐generation semi‐synthetic derivative of ergotamine tartrate that has been used effectively to treat migraine since 1945 1 and is listed as a first‐line treatment in migraine treatment guidelines from the American Academy of Neurology. 2 Studies of DHE mesylate via intravenous, intramuscular, subcutaneous, intranasal, and orally inhaled administration have consistently resulted in headache relief in 50% to 70% of the treated patients at 2 h after administration 3 , 4 , 5 , 6 , 7 , 8 and the safety profile is well described. 9 , 10
The first‐generation ergot‐based product ergotamine has been associated with vasospasm related events, for example, extremity gangrene due to the vasoconstrictive activity. Based on a literature review by the Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology most reports of myocardial and extremities ischemia events were based on single case reports and predominantly related to ergotamine tartrate use whereas adverse effects associated with DHE were extremely rare. 9 , 10 More recent pharmacological studies have shown that DHE and sumatriptan cause larger contractions in the meningeal arteries than in distal coronary arteries and that the effects of DHE are smaller than those of sumatriptan, with both inducing only slight contractions at clinical concentrations. 11
Despite its well‐described safety profile all DHE product labels contain a boxed warning regarding the risk of vasospasm due to increased plasma exposure with concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors. 12 , 13 , 14 This warning is not based on formal drug drug interaction (DDI) studies, and the only published formal human DDI study conducted with a non‐oral DHE product demonstrated little to no effect of the strong CYP3A4 inhibitor ketoconazole on DHE pharmacokinetics (PK) after pulmonary inhalation of 1 mg DHE. 15 DHE Cmax, AUC0–48 h, and AUC0–∞ were not statistically significantly different after DHE alone and DHE plus ketoconazole.
Moreover, in a DDI study in healthy subjects, the concomitant dosing with 9 mg oral DHE and 1600 mg ponsinomycin (potent CYP3A4 inhibiting macrolide antibiotic) resulted in 3–40‐fold increase in maximum DHE plasma levels, probably related to a reduction of its first‐pass elimination. 16 The observation that potent CYP3A4 inhibitors increase DHE plasma concentrations in the presence of oral, but not parenteral, DHE formulations is further corroborated by a mini pig study in which substantially increased DHE concentrations were shown following oral DHE administration in the presence of triacetyloleandomycin (potent CYP3A4 inhibiting macrolide antibiotic) as compared to only a slight pharmacokinetic interaction following intravenous DHE administration. 17
STS101 is a recently approved novel drug device combination product (Figure 1) containing 5.2 mg DHE for intranasal delivery indicated for the acute treatment of migraine with or without aura in adults. 18 Following nasal administration of STS101 in healthy subjects, the mean maximum plasma concentration was 2.1 ng/mL, the median time to maximum plasma concentration was approximately 0.5 h, and the apparent half‐life approximately 13 h. 19 This Phase 1 study was conducted to evaluate the PK, safety, and tolerability of single doses of 5.2 mg STS101, with and without concomitant dosing of itraconazole, a strong CYP3A4 and P‐gp inhibitor.
Figure 1.

STS101. STS101 use instructions: “Remove the blue tab at the top and deliver full dose with 3 pumps into one nostril.”
Methods
This study was approved and monitored by Advarra IRB, Columbia, MD, and was conducted at the Quotient Sciences Phase 1 Clinic in Miami, FL, in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice, the Declaration of Helsinki, and in compliance with United States Food and Drug Administration regulations. All subjects gave written informed consent before any study related procedures.
Study Population
Eligible participants were healthy subjects, 18 to 50 years old of any race and gender, with no clinically significant abnormality identified in the medical or laboratory evaluations, including a 12‐lead electrocardiogram (ECG). Exclusion criteria included any clinically significant central nervous system, cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions, and smoking within 12 months before the study. Use of drugs or foods known to interfere with metabolization of DHE via the cytochrome 3A4 P450 pathway or peripheral vasoconstrictors, for example, triptans, was not permitted. Use of nonprescription medications, including vitamins and natural, herbal, and dietary supplements, had to be discontinued 7 days prior to the screening visit.
Study Design and Treatments
This was a single‐center, single‐dose (in each period), open‐label, 2‐period, fixed sequence, pharmacokinetic and safety study in healthy subjects. All subjects were housed in the Phase 1 clinic for the whole duration of the study from 24 h before dosing in Period 1 to 48 h after drug administration in Period 2 (Figure 2). Eligible study subjects were administered a single dose of 5.2 mg STS101 intranasal powder on Day 1 in Period 1. Subjects took itraconazole for 15 days (200 mg QD with food) starting on Day 3 of Period 1 after the 48‐h blood draw. After the 13th dose of itraconazole the subjects received a single dose of 5.2 mg STS101 on Study Day 1 of Period 2. Each dose of STS101 was self‐administered under the supervision of the clinical research staff. Prior to the administration of STS101, the subjects blew their noses and then self‐administered the study medication. Nose blowing and sneezing events were recorded for 2 h after dosing. Each dose of itraconazole was taken by subjects under supervision of the clinical staff. Itraconazole is a strong CYP3A4 and P‐gp inhibitor and was dosed at 200 mg once daily as recommended for DDI studies by the Clinical Pharmacology Leadership Group (CPLG). 20 , 21 Itraconazole 100‐mg capsules were supplied by Northstar Rx LLC Memphis, TN. STS101 5.2 mg was supplied by Satsuma Pharmaceuticals, Raleigh, NC.
Figure 2.

Study schema.
Study Assessments
Vital signs (pulse rate, sitting blood pressure, and oral temperature) were recorded before dosing and post‐dose at 30 and 60 min and 2, 4, 24, and 48 h. Physical examinations were performed pre‐dose and post‐dose at 24 h. Adverse events were elicited pre‐dose and post‐dose at 24 and 48 h. An ECG was performed at screening, pre‐dose, and post‐dose at 30 and 90 min and at 2 and 24 h. Blood samples were taken for eligibility at screening and for routine clinical laboratory evaluations pre‐dose and post‐dose at 24 h. Nasal examinations were completed by the same trained and qualified physician using a 5‐item instrument evaluating the presence and severity of erythema, edema, rhinorrhea, bleeding, and ulceration pre‐dose and post‐dose at 60 min, and at 4, and 24 h. Blood samples to determine concentrations of DHE and the metabolite were obtained pre‐dose, and at 5, 10, 15, 20, 30, 45, 60, and 90 min and at 2, 4, 6, 8, 12, 24, 36, and 48 h post‐dose.
Bioanalytical Methods
Quantitative liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) was used to determine plasma levels of parent DHE and its primary metabolite, 8′‐OH‐DHE. Following extraction, samples were subjected to LC‐MS/MS analysis in electrospray positive ion mode using a Sciex API 5000 machine. The method was linear over the standard concentration ranges studied (8 to 8000 pg/mL for DHE and 19 to 1900 pg/mL for 8′‐OH‐DHE); imprecision (coefficient of variation [CV]) did not exceed 5.6% (CV on CS: DHE: 3.7%/β: 5.6%/α: 5.1%). Replicate analyses of intra‐ and inter‐batch DHE quality control samples showed accuracy of 98.2%–108.5% and assay imprecision <3.7%. Replicate 8′‐OH‐DHE analyses of intra‐ and inter‐batch quality control samples showed accuracy of 100.7%–107.9% and 94.5%–107.8% and assay imprecision <3.9% and <18.4% for β‐8′‐OH‐DHE and α‐8′‐OH‐DHE, respectively. Mean (standard deviation) recovery from human plasma at low, medium, and high levels were 98.2%, 96.5%, and 92.3% for DHE, 97.6%, 96.9%, and 92.5% for β‐8′‐OH‐DHE and 90.7%, 88.7%, and 84.2% for α‐8′‐OH‐DHE. All bioanalytical analyses were performed by Syneos/Inventive Health, Quebec City, Canada.
Statistical Analysis
No formal statistical calculation of sample size was performed. Based on similar previous studies, the number of subjects enrolled in this study was deemed sufficient to generate meaningful safety and PK data. The PK data analysis set included all subjects who received at least one dose of the investigational drug, were compliant with study procedures, and had bioanalytical data available from at least one treatment. DHE and 8′‐OH‐DHE concentrations through 48 h after dosing were used to calculate PK parameters, including, but not limited to: Cmax, Tmax, AUC0–48 h, AUClast, AUC0–inf, and t1/2. The comparative bioavailability of DHE and 8′‐OH‐DHE for STS101 with and without itraconazole was assessed using a linear repeated measures mixed‐effect model on natural log‐transformed PK parameters (AUClast, AUCinf, and Cmax). As the order of treatment was fixed, a variance component matrix was used. For each comparison, estimates of the mean difference and corresponding 90% confidence interval (CI) were obtained from the model and exponentiated to provide an estimate of the geometric least squares means ratio and the 90% CI of the ratio. Phoenix WinNonlin (Certara, Princeton, NJ), RStudio (RStudio, Boston, MA), R Software (R Foundation for Statistical Computing, Vienna, Austria), and SAS (SAS Institute, Cary, NC) were used for the analyses and generation of tables, listings, and figures.
Results
Subjects
Thirty‐one female (45%) and male (55%) Hispanic subjects with a mean age of 38 years were enrolled of which 30 completed all study activities. One subject withdrew consent for personal reasons after completing all study activities for Period 1. All 31 subjects enrolled into the study were included in the safety analysis. The PK analyses of DHE and total 8′‐OH‐DHE is based on 31 subjects for 5.2 mg STS101 alone and 30 subjects for 5.2 mg STS101 + itraconazole. Baseline demographics for the subjects can be found in Table 1.
Table 1.
Study Subject Baseline Demographics
| Characteristics | N = 31 |
|---|---|
| Sex, n | |
| Male | 17 (54.8) |
| Female | 14 (45.2) |
| Age at informed consent, years | |
| Mean (SD) | 38.0 (7.9) |
| Minimum, maximum | 20, 50 |
| Race, n | |
| Black or African American | 5 (16.1) |
| White | 26 (83.9) |
| Ethnicity, n | |
| Hispanic or Latino | 31 (100) |
| Height, cm | |
| Mean (SD) | 168.3 (8.3) |
| Minimum, maximum | 153.0, 185.0 |
| Weight, kg | |
| Mean (SD) | 76.1 (9.9) |
| Minimum, maximum | 60.1, 94.4 |
| Body mass index, kg/m2 | |
| Mean (SD) | 26.9 (3.1) |
| Minimum, maximum | 20.1, 32.0 |
Evaluation of Plasma Concentrations
Plasma DHE exposure (mean Cmax and AUC) was slightly higher for STS101 with itraconazole (Table 2, Figure 3). Geometric mean (CV%) Cmax was 2440 (41.3%) pg/mL for STS101 alone and 2770 (32.3%) pg/mL for STS101 with itraconazole. Geometric mean (CV%) AUC0–48 was 10,900 (33.3%) h·pg/mL for STS101 alone and 12,900 (24.8%) h·pg/mL for STS101 with itraconazole. The geometric LSM ratios of STS101 with itraconazole to STS101 alone were 114.21%, 118.51%, and 118.72% for Cmax, AUC0–48, and AUCinf, respectively, and the lower bound of the 90% CI was greater than 100.00% for all the three PK parameters (Table 3).
Table 2.
Summary of Geometric Mean (CV%) for DHE PK Parameters by Treatment
| Treatment | Cmax (pg/mL) | Tmax (Arithmetic Median, min/max; h) | AUC0–48 (h·pg/mL) | AUC0–inf (h·pg/mL) | t1/2 (h) |
|---|---|---|---|---|---|
| STS101 Alone (N = 31) | 2440 (41) | 0.33 (0.25, 1.00) | 10,900 (33) | 11,400 (33) | 11.6 (18) |
| STS101 + Itraconazole (N = 30) | 2780 (32) | 0.42 (0.25, 1.5) | 12,900 (25) | 13,500 (25) | 12.3 (21) |
Figure 3.

Mean (± SD) plasma DHE concentration versus time following STS101 5.2 mg taken alone and with itraconazole (semi‐logarithmic scale).
Table 3.
Comparison of DHE PK Parameters (Geometric LSM) by Treatment
| STS101 + Itraconazole (N = 30) | STS101 Alone (N = 30) | |||||
|---|---|---|---|---|---|---|
| Parameter | N | Geometric LSM | N | Geometric LSM | STS101 + Itraconazole / STS101 Ratio (%) | 90% Confidence Interval |
| Cmax (pg/mL) | 30 | 2780 | 31 | 2440 | 114.21 | (100.79, 129.42) |
| AUC0–48 (h·pg/mL) | 30 | 12,900 | 31 | 10,900 | 118.51 | (107.72, 130.39) |
| AUCinf (h·pg/mL) | 30 | 13,500 | 31 | 11,400 | 118.72 | (108.06, 130.44) |
AUC0–48, AUC from time zero to 48 h post‐dose; AUCinf, area under the concentration–time curve (AUC) extrapolated to infinity; Cmax, maximum observed plasma drug concentration; LSM, least‐squares mean.
Plasma total 8′‐OH‐DHE exposure (mean Cmax and AUC) was higher for STS101 with itraconazole than STS101 alone (Table 4). Geometric mean (CV%) of Cmax was 106 (60.1%) pg/mL for STS101 alone and 451 (78.1%) pg/mL for STS101 with itraconazole. Geometric mean (CV%) of AUC0–48 was 1210 (44.1%) h·pg/mL for STS101 alone and 3190 (54.9%) h·pg/mL for STS101 with itraconazole. The metabolite to parent ratios for Cmax and AUCinf were 4‐fold and 2‐fold higher for STS101 with itraconazole versus STS101 alone (Table 5).
Table 4.
Summary of Geometric Mean (CV%) for 8′‐OH‐DHE PK Parameters by Treatment
| Treatment | Cmax (pg/mL) | Tmax (Arithmetic Median, min, max; h) | AUC0–48 (h·pg/mL) | AUC0–inf (h·pg/mL) | t1/2 (h) |
|---|---|---|---|---|---|
| STS101 Alone (N = 31) | 106 (60) | 2 | 1210 (44) | 1410 (39) | 14.9 (24) |
| STS101 + Itraconazole (N = 30) | 451 (78) | 2 | 3190 (55) | 3670 (41) | 14.9 (29) |
Table 5.
Comparison of 8′‐OH DHE PK Parameters (Geometric LSM) by Treatment
| STS101 + Itraconazole (N = 30) | STS101 Alone (N = 30) | |||||
|---|---|---|---|---|---|---|
| Parameter | N | Geometric LSM | N | Geometric LSM | STS101 + Itraconazole / STS101 Ratio (%) | 90% Confidence Interval |
| Cmax (pg/mL) | 30 | 452 | 31 | 106 | 427.09 | (358.54, 508.74) |
| AUC0–48 (h·pg/mL) | 30 | 3160 | 31 | 1210 | 261.41 | (231.91, 294.66) |
| AUCinf (h·pg/mL) | 29 | 3640 | 30 | 1410 | 257.87 | (228.8, 290.65) |
AUC0–48, AUC from time zero to 48 h post‐dose; AUCinf, area under the concentration–time curve (AUC) extrapolated to infinity; Cmax, maximum observed plasma drug concentration; LSM, least‐squares mean.
Safety
A total of 14 treatment emergent adverse events (TEAEs) were reported in 10 of the 31 subjects (32.3%) after administration of a single dose of 5.2 mg STS101 alone, and a total of 1 TEAE was reported in 1 of the 30 subjects (3.3%) after administration of a single dose of 5.2 mg STS101 with itraconazole (Table 6). All TEAEs that occurred during the study were mild in severity and resolved spontaneously or with supportive care, for example, application of warm compresses or cold towel for headache. Mean values for systolic blood pressure, diastolic blood pressure, pulse rate, and oral temperature were comparable to baseline values for each treatment at each postbaseline assessment and were comparable between the two treatments. In one subject in Period 2, a systolic blood pressure value of 155 mmHg at 30 min post‐dose coincided with the subject's maximum DHE plasma concentration of 4270 pg/mL. The subsequent blood pressure values in this subject showed some variability, and the highest systolic value of 160 mmHg was recorded at 8 h post‐dose when the DHE plasma concentration was 722 pg/mL. There were no clinically significant laboratory abnormalities during the study, and all laboratory data were comparable between the two treatments. Mean values for ECG parameters (heart rate, PR interval, QRS duration, QT interval, QTcF interval, and RR interval) were comparable to baseline values for each treatment at each postbaseline assessment and were comparable between the two treatments. There were no clinically meaningful differences in the standardized assessment of the nasal cavity between the two treatments.
Table 6.
Treatment Emergent Adverse Events
| Treatment | ||
|---|---|---|
| MedDRA System Preferred Term | 5.2 mg STS101 Alone (N = 31) n (%) | 5.2 mg STS101 + Itraconazole (N = 30) n (%) |
| Number (%) of subjects with at least one event a | 10 (32.3) | 1 (3.3) |
| Headache | 2 (6.5) | 0 |
| Skin irritation | 2 (6.5) | 0 |
| Ocular hyperemia | 2 (6.5) | 0 |
| Abdominal distension | 1 (3.2) | 0 |
| Constipation | 1 (3.2) | 0 |
| Nausea | 1 (3.2) | 0 |
| Facial pain | 0 | 1 (3.3) |
| Eye irritation | 1 (3.2) | 0 |
| Nasal congestion | 1 (3.2) | 0 |
| Nasal discomfort | 1 (3.2) | 0 |
| Neck pain | 1 (3.2) | 0 |
Subjects who experienced the same event more than once were counted only once for the preferred term; TEAEs that occurred after the first and before the second dose of STS101 were attributed to 5.2 mg STS101 alone, and TEAEs that occurred after the second dose of STS101 were attributed to 5.2 mg STS101 plus itraconazole.
Discussion
DHE has been a staple in migraine therapy for over 70 years and is recognized in migraine treatment guidelines as being a safe and effective initial treatment option for moderate and severe migraine attacks. 22 , 23 , 24 DHE is a second‐generation semi‐synthetic ergot alkaloid product derived from the Claviceps purpurea fungus. Unlike the first‐generation ergot‐based product ergotamine, reports of myocardial and extremities ischemia events with DHE are extremely rare. 9 , 10 Moreover, recent pharmacological studies have shown that the vasoconstrictive effects of DHE on coronary arteries are smaller than those of sumatriptan, with both inducing only slight contractions at clinical concentrations. 11
Nevertheless, all DHE products contain a boxed warning regarding the risk of vasospasm due to increased plasma exposure with concomitant use of strong CYP3A4 inhibitors.
This healthy subject study was designed to evaluate the tolerability, safety, and PK profile of STS101, a novel drug–device combination product containing a powder formulation of DHE. The data from this study shows a small interaction of co‐administered itraconazole and STS101 leading to an increase in DHE Cmax of approximately 14% and an increase in DHE AUCinf of 19%. These plasma concentrations are below the concentrations previously reported for intramuscular administered DHE and do not indicate an increase in risk for patients when STS101 is co‐administered with a strong CYP3A4 inhibitor. 19
The increased formation of 8‐OH‐DHE metabolite in subjects taking a strong CYP3A4 inhibitor is consistent with the results reported by Kellerman et al in a similar study where the effects of ketoconazole on inhaled DHE pharmacokinetics were evaluated. 15 Itraconazole inhibits both P‐glycoprotein and CYP3A4, which may explain the increase in the 8‐OH‐DHE metabolite as described by others. 15 , 25 Importantly, the mean peak 8′‐OH‐DHE concentration of approximately 450 pg/mL in the presence of itraconazole is comparable to concentrations resulting in no receptor activation in a receptor binding study. 26 Moreover, at no timepoint over 48 h after concomitant dosing of STS101 and itraconazole did the combined DHE and 8′‐OH‐DHE concentrations exceed the maximum DHE concentration alone indicating that even if 8′‐OH‐DHE were pharmacologically active it is not likely to increase the risk of clinical adverse events. Lastly, the elimination half‐life of both DHE and 8‐OH‐DHE were not prolonged following itraconazole, providing reassurance that prolonged pharmacologic effect from the CYP3A4 inhibition is unlikely.
All TEAEs were mild in nature, transient and related to the nasal route of administration or known effects of DHE mesylate, for example, headache or nasal discomfort. Importantly, the frequency of reported TEAs was higher when STS101 was dosed alone versus when dosed in the presence of itraconazole. All other clinical safety evaluations (laboratory tests, ECGs, nasal evaluations, physical evaluations, and vital signs) showed no difference between the two treatment arms.
This study had important limitations. First, for operational reasons the study treatments were given in a fixed sequence. Based on prior PK data, 19 no carry‐over effects were expected on the DHE plasma concentrations. However, the subject's perception and reporting of adverse events in the second period may have been biased by their experience in the first period. Second, as all subjects were Hispanic, the generalizability of these findings to non‐Hispanic groups is uncertain since there are differences by ethnicity in the distribution of polymorphisms in the CYP3A4 gene and differences in drug metabolism. 27 , 28 Finally, these results were obtained from healthy volunteers, not patients with migraine. Though differences in metabolic processes are possible, STS101 has a similar PK profile in migraine subjects as in healthy volunteers. 29
In conclusion, the results from this study showed that DHE plasma Cmax and AUCinf are increased (by approximately 14% and 19%, respectively) when STS101 was co‐administered with itraconazole. However, these increases are within the 90% confidence interval of 80%–125%, proposed as a default no‐effect boundary for DDI assessment. 30 These increases were not associated with clinical sequelae, and STS101 was well tolerated by healthy subjects when taken alone and when co‐administered with itraconazole. In conclusion, no clinically meaningful DDIs were seen when STS101 was co‐administered with a strong CYP3A4 inhibiting drug.
Conflicts of Interest
Detlef Albrecht was an employee and stockholder of Satsuma Pharmaceuticals, Inc. at the time of study conduct and currently acts as a consultant for Satsuma; Elizabeth Hussey is an employee of Allucent; Richard B. Lipton has been a consultant, advisory board member, and/or has received honoraria from AEON, Allergan/Abbvie, American Academy of Neurology, American Headache Society, Amgen, Axsome, Biohaven Pharmaceuticals, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Impel Neuropharma, Lundbeck, Merck, Pfizer, Satsuma, Teva, and Vector. In addition, he has stock or stock options in Cooltech, Manistee, and NuVieBio.
Funding
The study was funded by Satsuma Pharmaceuticals, Inc.
Acknowledgments
The authors would like to thank John Kollins, Mic Iwashima, Rob Schultz, and Shannon Strom for their support in study design and conduct; Marie‐Eve Coulombe for managing the bioanalytical activities; Patti Butler, Maricer Escalon, Julie Costo, Isis Fonseca, Alexandra Ruiz, Mable Harris, Adriana Tijerino, Maria Cuartas, Rocio Martin, Laura Gonzalez, Olga Acosta, Isbel Monto, Elisabeth Victor, Christian Garcia, and Michelle Suarez for performing all study activities at the Phase 1 site; Suzette V. Sanchez‐Cohen and Esther Pacheco for clinical data management; Antonio Regueira, Jonathan Marin, Manuel Riveria, and Nadege Noel for pharmacy support; Ann Weltevreden Penix for statistical analysis; Bridgette Johnson for database management; Ed Cabana for clinical monitoring; Cina Salas for writing assistance; and Tara Cruz for administrative support.
References
- 1. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43(2):144‐166. [DOI] [PubMed] [Google Scholar]
- 2. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3‐20. [DOI] [PubMed] [Google Scholar]
- 3. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507‐517. [DOI] [PubMed] [Google Scholar]
- 4. Carleton SC, Shesser RF, Pietrzak MP, et al. Double‐blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med. 1998;32(2):129‐138. [DOI] [PubMed] [Google Scholar]
- 5. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001;41(10):976‐980. [DOI] [PubMed] [Google Scholar]
- 6. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol. 1996;53(12):1285‐1291. [DOI] [PubMed] [Google Scholar]
- 7. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995‐997. [DOI] [PubMed] [Google Scholar]
- 8. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double‐blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996;53(2):180‐184. [DOI] [PubMed] [Google Scholar]
- 9. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus [RETIRED]. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology. 1995;45(3 Pt 1):577‐584. [DOI] [PubMed] [Google Scholar]
- 10. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37(Suppl 1):S33‐S41. [PubMed] [Google Scholar]
- 11. Labruijere S, Chan KY, de Vries R, et al. Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein. Cephalalgia. 2015;35(2):182‐189. [DOI] [PubMed] [Google Scholar]
- 12. D.H.E . 45® Prescribing Information. Bridgewater (NJ): Valeant Pharmaceuticals; 2019. [Google Scholar]
- 13. Trudhesa™Prescribing Information . (dihydroergotamine mesylate) nasal spray. Impel NeuroPharma Inc. Milano (IT): Mipharm, S.p.A.; 2019. [Google Scholar]
- 14. Migranal® Prescribing Information . Aliso Viejo (CA): Valeant Pharmaceuticals; 2019. [Google Scholar]
- 15. Kellerman D, Kori S, Forst A, et al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia. 2012;32(2):150‐158. [DOI] [PubMed] [Google Scholar]
- 16. Couet W, Mathieu HP, Fourtillan JB. Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally. Fundam Clin Pharmacol. 1991;5(1):47‐52. [DOI] [PubMed] [Google Scholar]
- 17. Martinet M, Kiechel JR. Interaction of dihydroergotamine and triacetyloleandomycin in the minipig. Eur J Drug Metab Pharmacokinet. 1983;8(3):261‐267. doi: 10.1007/BF03188756 [DOI] [PubMed] [Google Scholar]
- 18. ATZUMI™ Prescribing Information 2025; Satsuma Pharmaceuticals; satsumarx.com.
- 19. Lipton RB, Albrecht D, Bermudez M, Hu J, Hussey E, Levy J. A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE mesylate in healthy adults. Headache. 2024;64(3):266‐275. [DOI] [PubMed] [Google Scholar]
- 20. Itraconazole Capsules Prescribing Information 2020; Northstar Rx LLC.
- 21. Liu L, Bello A, Dresser MJ, Best practices for the use of itraconazole as a replacement for ketoconazole in drug‐drug interaction studies. J Clin Pharmacol. 2016;56(2):143‐151. [DOI] [PubMed] [Google Scholar]
- 22. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(Suppl 4):S212‐S220. [DOI] [PubMed] [Google Scholar]
- 23. Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010;50(8):1353‐1361. [DOI] [PubMed] [Google Scholar]
- 24. Silberstein SD, Newman LC, Marmura MJ, Nahas SJ, Farr SJ. Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. Curr Med Res Opin. 2013;29(7):861‐867. [DOI] [PubMed] [Google Scholar]
- 25. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441‐1458. [DOI] [PubMed] [Google Scholar]
- 26. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache. 2009;49(10):1423‐1434. [DOI] [PubMed] [Google Scholar]
- 27. Guttman Y, Nudel A, Kerem Z. Polymorphism in cytochrome P450 3A4 is ethnicity related. Front Genet. 2019;10:224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Darney K, Testai E, Buratti FM, et al. Inter‐ethnic differences in CYP3A4 metabolism: a Bayesian meta‐analysis for the refinement of uncertainty factors in chemical risk assessment. Comp Tox. 2019;12:100092. [Google Scholar]
- 29. Albrecht D, Strom S. DHE plasma concentration and clinical response relationship: an in‐office PK‐PD study [Poster P‐305]. 67th Annual Scientific Meeting of the American Headache Society; 2025 Jun 19–22; Minneapolis (MN).
- 30. US Food and Drug Administration , Guidance for Industry: M12 Drug Interaction Studies 2024; https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/m12‐drug‐interaction‐studies
